CONTACT US
egnite Research

Artificial Intelligence to Assist Physicians in Identifying Patients with Severe Aortic Stenosis

BACKGROUND

Severe aortic stenosis (AS) remains a life-threatening form of valvular heart disease. Missed diagnosis of severe AS can lead to a delay in treatment and poor outcomes, but there are limited tools available to help physicians minimize the risk of missed diagnoses.

OBJECTIVE

Here, a Diagnostic Precision Algorithm was developed from a deidentified dataset of 1,147,157 echocardiographic reports from 35 institutions (egnite Database; egnite, Inc., Aliso Viejo, CA, USA) to help physicians identify patients who may have incorrectly not received a severe AS diagnosis and prioritize these findings for secondary clinical review.

METHODS

Inclusion criteria required the presence of three standard Doppler indices (aortic valve area [AVA], jet velocity [JV], and mean pressure gradient [MPG]), with at least one in the severe AS range (per AHA/ACC criteria), and documented assessment of AS severity. Included reports were divided into training/validation (N = 18,040) and test (N = 4,533) datasets. Using a decision tree algorithm, a Severe AS Index that estimates the likelihood that a patient with similar values would have severe AS diagnosed was developed from the training/validation dataset using AVA, JV, and MPG measurements, as well as left ventricular ejection fraction (LVEF) when available. This was compared to the reported interpretation of the echocardiogram, which was extracted using a validated natural language processing algorithm that demonstrated 100% accuracy across a sample of 600 echocardiographic reports. When the prediction of the Severe AS Index and the report interpretation disagreed, the patient was flagged for secondary review.

RESULTS

Across the test dataset, the Diagnostic Precision Algorithm successfully predicted the actual severe AS population proportion with an average error of 2.1% points when LVEF was available and 2.2% points when LVEF was not available.

CONCLUSIONS

The Diagnostic Precision algorithm was highly accurate at identifying the likelihood of severe AS diagnosis and applying this information to prioritize physician follow-up for patients who may have undiagnosed severe disease.

View the Publication

Thomas JD, Petrescu OM, Moualla SK, Dobbles M, Hays JC, Rodriguez E, Barnhart GR. Artificial intelligence to assist physicians in identifying patients with severe aortic stenosis. Intelligence Based Medicine. 2022;6:100059. doi: 10.1016/j.ibmed.2022.100059​​

Follow egnite on social:

Linkedin Twitter Youtube

Related Articles
egnite Research

Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
egnite Research

From Black Box to Breakthrough: Unlocking Hidden Care Patterns with LLM-Enriched Data

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.